FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to using phenylethenyl- or phenylethynyl-derivatives as antagonists of glutamates receptors. Invention describes using compound of the general formula (I):
wherein each among R1, R2, R3, R4 and R5 means independently of one another hydrogen atom, (C1-C6)-alkyl, -(CH2)n-halogen, (C1-C6)-alkoxy-group, -(CH2)n-NRR', -(CH2)n-N(R)-C(O)-C1-C6)-alkyl, phenyl or pyrrolyl that can be unsubstituted or substituted with one or more (C1-C6)-alkyl; each among R, R' and R'' means independently of one another hydrogen atom or (C1-C6)-alkyl; A means -CH=CH- or C≡C; B means 
,
, 
, 
, 
or 
wherein R6 means hydrogen atom, (C1-C)-alkyl, -(CH2)n-C(O)OR, or halogen atom; R7 means hydrogen atom, (C1-C6)-alkyl, -(CH2)n-C(O)OR', halogen atom, nitro-group or oxodiazolyl group that can be unsubstituted or substituted with (C1-C6)-alkyl or cycloalkyl; R8 means hydrogen atom, (C1-C6)-alkyl, -(CH2)n-OH, -(CH2)n-C(O)OR'' or phenyl; R9 means (C1-C6)-alkyl; R10 and R11 mean hydrogen atom; R12 means -(CH2)n-N(R)-C(O)-(C1-C6)-alkyl; R13 means hydrogen atom; each R14, R15, R16 and R17 independently of one another means hydrogen atom or (C1-C6)-alkoxy-group; each R18, R19 and R20 independently of one another means hydrogen atom; R21 means hydrogen atom or (C1-C6)-alkyl; R22 means hydrogen atom, (C1-C6)-alkyl or (C1-C6)-alkyl comprising one or more substitutes chosen from groups hydroxy- or halogen atom; R23 means hydrogen atom, (C1-C6)-alkanoyl or nitro-group; each among R24, R25 and R26 independently of one another means hydrogen atom or (C1-C6)-alkyl; n = 0, 1, 2, 3, 4, 5 or 6; X means -O- or -S-; Y means -CH= or -N=, and its pharmaceutically acceptable salts used in preparing medicinal agents designates for treatment or prophylaxis of disorders mediated by mGluR5-receptors. Also, invention describes compounds of the formula (I-A), compound of the formula (I-B-1) given in the invention description, and a medicinal agent used in treatment or prophylaxis of disorders mediated by mGluR5-receptors.
EFFECT: valuable medicinal properties of compounds.
44 cl, 1 tbl, 44 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMIDAZOLE DERIVATIVES AS mGluR5 ANTAGONISTS | 2010 |
|
RU2527106C2 |
| DERIVATIVES OF DIHYDROBENZO[b][1,4]DIAZEPINE-2-ONE AS I mGluR2 ANTAGONISTS | 2002 |
|
RU2270197C2 |
| TYROSINE KINASE INHIBITORS | 2008 |
|
RU2445309C2 |
| BENZOTHIAZOLE DERIVATIVES | 2005 |
|
RU2382782C2 |
| PHENYLACETIC ACID DERIVATIVES, THEIR INTERMEDIATES, AND AGENTS CONTAINING THEREOF | 1995 |
|
RU2165411C2 |
| 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | 2009 |
|
RU2513086C2 |
| DERIVATIVES OF N-(IMIDAZOPYRIMIDIN-7-YL)-HETEROARYLAMIDES AND THEREOF APPLICATION AS PDE10A INHIBITORS | 2011 |
|
RU2562066C2 |
| DERIVATIVES OF BENZODIAZEPINE AND MEDICINAL AGENT COMPRISING THEREOF | 2000 |
|
RU2259360C2 |
| OXAZOLINE DERIVATIVES FOR TREATING CNS DISORDERS | 2010 |
|
RU2569887C2 |
| GUANIDIN DERIVATIVES AND THEIR APPLICATION AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | 2004 |
|
RU2337911C2 |
